FindTrial
Sign In

Placebo to match aficamten

DRUG2 trials

Sponsors

Cytokinetics

Conditions

Obstructive Hypertrophic Cardiomyopathy (oHCM)

Phase 3

Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM
CompletedNCT05186818
CytokineticsObstructive Hypertrophic Cardiomyopathy (oHCM)
Start: 2022-02-01End: 2023-12-18Updated: 2026-03-03
Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM
CompletedNCT05767346
CytokineticsObstructive Hypertrophic Cardiomyopathy (oHCM)
Start: 2023-06-20End: 2025-03-28Updated: 2025-05-02

Related Papers

Efficacy of aficamten according to geographic location of patients with hypertrophic obstructive cardiomyopathy
ESC Heart Failure2026-01-16
Efficacy and Safety of Aficamten in Children and Adolescents With Obstructive Hypertrophic Cardiomyopathy: Study Design and Rationale of CEDAR-HCM.
2025-12-05
Aficamten in Obstructive Hypertrophic Cardiomyopathy: A Multidomain, Patient-Level Analysis of the MAPLE-HCM Trial.
2025-11-181 citations
Effect of Aficamten vs Metoprolol on Patient-Reported Health Status in Obstructive Hypertrophic Cardiomyopathy.
2025-11-18
Abstract 4370461: Aficamten is safe and effective in oHCM with comorbidities obesity, hypertension, and diabetes: a SEQUOIA-HCM sub-study
Circulation2025-11-03
Abstract 4361884: Improvement in Echocardiographic Measures of Diastolic Function Reflects Improved Exercise Performance in Obstructive Hypertrophic Cardiomyopathy: Insights From the SEQUOIA-HCM Trial
Circulation2025-11-03
Abstract 4365842: Chronic Aficamten Treatment Results in Sustained Favorable Cardiac Remodeling in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy: Insights From the FOREST-HCM Trial
Circulation2025-11-03
Characterization and Application of Novel Exercise Recovery Patterns That Reflect Cardiac Performance: A Substudy of the SEQUOIA-HCM Trial
Circulation2025-09-051 citations
Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy
New England Journal of Medicine2025-08-3020 citations
Effect of Aficamten Compared With Metoprolol on Echocardiographic Measures in Symptomatic Obstructive Hypertrophic Cardiomyopathy: MAPLE-HCM.
2025-08-27
Aficamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: 48-Week Results From FOREST-HCM.
2025-06-192 citations
Efficacy of aficamten in patients with obstructive hypertrophic cardiomyopathy and mild symptoms: results from the SEQUOIA-HCM trial
European Heart Journal2025-05-162 citations
Concomitant Aficamten and Disopyramide in Symptomatic Obstructive Hypertrophic Cardiomyopathy.
2025-04-021 citations
Clinical Evaluation of the Effect of Aficamten on <scp>QT</scp>/<scp>QTc</scp> Interval in Healthy Participants
Clinical and Translational Science2025-04-014 citations
Aficamten vs Metoprolol for Obstructive Hypertrophic Cardiomyopathy
JACC Heart Failure2025-02-0115 citations
Abstract 4140102: Changes in EQ-5D-5L with Aficamten in Obstructive Hypertrophic Cardiomyopathy (oHCM): the SEQUOIA-HCM Trial
Circulation2024-11-112 citations
Clinical application of biomarkers in obstructive hypertrophic cardiomyopathy: insights from SEQUOIA-HCM
European Heart Journal2024-10-012 citations
Impact of Aficamten on Disease and Symptom Burden in Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM.
2024-09-3028 citations
Aficamten and Cardiopulmonary Exercise Test Performance
JAMA Cardiology2024-09-0416 citations
Effect of Aficamten on Cardiac Structure and Function in Obstructive Hypertrophic Cardiomyopathy: SEQUOIA-HCM CMR Substudy.
2024-09-0135 citations

8 more papers not shown